Previous Close | 33.59 |
Open | 33.80 |
Bid | 33.65 x 900 |
Ask | 33.70 x 800 |
Day's Range | 33.30 - 33.84 |
52 Week Range | 9.93 - 47.97 |
Volume | 81,984 |
Avg. Volume | 309,262 |
Market Cap | 1.134B |
Beta (5Y Monthly) | 1.49 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.04 |
Earnings Date | May 12, 2021 - May 17, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 56.25 |
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company. The freezer will be a critical component in this customer's cold chain management of several allogeneic cell therapies in development.
HRC vs. BLFS: Which Stock Is the Better Value Option?
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appointed Amy DuRoss, chief executive officer of Vineti, and Rachel Ellingson, senior vice president and chief strategy officer at Zimmer Biomet to its board of directors effective immediately.